pharmaceutical-investing Inovio Develops Novel H3N2 Influenza DNA Vaccine That Generates Cross-Reactive Responses and Provides Complete Protection Against Lethal Preclinical Challenges
CoTec Forms Subsidiary, CoTec Copper, To Accelerate Investment Activities In Copper Tailings and Copper Sulfide Deposits
